A Dose-masked Study of Intravitreal EYE103 in Participants With NVAMD or Macular Edema Following BRVO

Recruiting

Phase 2

EYE103A Dose-masked Study of Intravitreal EYE103 in Participants With NVAMD or Macular Edema Following BRVO

Sponsor:

EyeBiotech Ltd.

Code:

NCT07205887

Conditions

Neovascular Age-Related Macular Degeneration (NVAMD)

Branch Retinal Vein Occlusion (BRVO)

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

EYE103

Aflibercept 2.0 mg

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-10-10. This information was provided to ClinicalTrials.gov by EyeBiotech Ltd. on 2025-10-03.